Friday, 2 March 2018

New Drugs approved

Durvalumab - Stops interaction between PD1 and CD80 - Approved for unresectable Stage III Non Small Cell Lung Cancer.

Ademaciclib - As a first line in combination with aromatase inhibitor in ER + , HER2NEU -ve advanced or metastatic breast cancer.
Action - Blocks CDK 4/6.

No comments:

Post a Comment